Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• CEO Martine Rothblatt sold 9,500 United Therapeutics shares for approximately $5.05 million at an average price of $531.38, reducing her position by 2.84% to 324,443 shares.
• United Therapeutics shares fell 1.7% to $529.66. The company beat quarterly earnings expectations with EPS of $7.27, though revenue of $783.3 million missed estimates and declined 1.9% year over year.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $646, while institutional investors own 94.08% of the stock.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 9,500 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $531.38, for a total value of $5,048,110.00. Following the transaction, the chief executive officer owned 324,443 shares of the company's stock, valued at approximately $172,402,521.34. The trade was a 2.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Down 1.7%

UTHR traded down $9.18 on Monday, reaching $529.66. 394,230 shares of the company traded hands, compared to its average volume of 494,128. The company has a market cap of $22.72 billion, a P/E ratio of 18.95, a price-to-earnings-growth ratio of 1.82 and a beta of 0.59. United Therapeutics Corporation has a one year low of $292.34 and a one year high of $609.35. The firm has a fifty day simple moving average of $539.43 and a two-hundred day simple moving average of $534.71.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The business had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same period last year, the company posted $6.41 earnings per share. The company's quarterly revenue was down 1.9% compared to the same quarter last year. On average, equities analysts forecast that United Therapeutics Corporation will post 26.32 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Leuthold Group LLC boosted its position in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company's stock valued at $5,200,000 after buying an additional 3,126 shares during the period. UBS Group AG increased its holdings in shares of United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company's stock valued at $110,045,000 after acquiring an additional 70,445 shares during the last quarter. Nicholas Investment Partners LP increased its stake in United Therapeutics by 478.5% in the fourth quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company's stock valued at $2,218,000 after purchasing an additional 3,766 shares during the last quarter. LBP AM SA acquired a new stake in United Therapeutics during the 4th quarter worth $9,745,000. Finally, M&T Bank Corp increased its position in shares of United Therapeutics by 171.6% during the fourth quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company's stock worth $1,531,000 after purchasing an additional 1,985 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on UTHR. Royal Bank Of Canada dropped their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a research report on Thursday. JPMorgan Chase & Co. upped their price target on shares of United Therapeutics from $685.00 to $687.00 and gave the company an "overweight" rating in a research note on Thursday, July 23rd. TD Cowen restated a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. Wells Fargo & Company raised shares of United Therapeutics from an "equal weight" rating to an "overweight" rating and raised their target price for the stock from $575.00 to $735.00 in a report on Thursday, May 7th. Finally, Bank of America decreased their price target on United Therapeutics from $620.00 to $613.00 and set a "neutral" rating for the company in a report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $646.00.

United Therapeutics Company Profile

United Therapeutics Corporation NASDAQ: UTHR is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source